Precision Medicine in Liver and Lung Transplantation: Integrating Immunology, Regenerative Therapies, and Computational Advances

Liver and lung transplantation remain among the most intricate and resource-intensive arenas in modern medicine, challenged by organ scarcity, immunological complexities, and the persistent threat of rejection. According to recent WHO and UNOS reports, approximately 100,000 patients globally await liver transplants annually, with only 30-40% receiving transplants, resulting in waitlist mortality rates of 15-20%. Similarly, lung transplant demand exceeds supply by a factor of 4:1, with 5-year survival rates remaining at 60-65%. This article outlines the evolving landscape of liver and lung transplantation, with a focus on the intersection of immunological science, regenerative medicine, and computational advances. It aims to synthesize current challenges and emerging therapeutic strategies, emphasizing the transformative potential of precision medicine and advanced immunomodulation techniques. Recent decades have witnessed a paradigm shift from standardized immunosuppression toward individualized, data-driven care. Advances in molecular immunology have revealed complex cellular interactions and rejection pathways, informing targeted therapies such as extracorporeal photopheresis (ECP), immune checkpoint modulation, and the engineering of regulatory T cells. Regenerative medicine, including mesenchymal stem cells, iPSC-derived tissues, and gene editing, offers new avenues for organ repair and tolerance induction. Meanwhile, artificial intelligence and digital health platforms enable predictive modeling, risk stratification, and real-time monitoring, optimizing patient selection and management. Nanotechnology and advanced diagnostics, such as liquid biopsy and single-cell sequencing, further refine graft surveillance and intervention. These developments are situated within an ethical, regulatory, and economic context, underscoring the need for global collaboration and equitable access. The future of liver and lung transplantation lies in the convergence of precision immunology, regenerative strategies, and computational innovation. Interdisciplinary, personalized approaches promise to enhance graft survival, patient outcomes, and the sustainable integration of cutting-edge therapies into global healthcare systems.